FMP

FMP

Enter

PCVX - Vaxcyte, Inc.

Profile of Vaxcyte, Inc.(PCVX), Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to pr

About

ceo

Mr. Grant E. Pickering M.B.A.

sector

Healthcare

industry

Biotechnology

website

https://vaxcyte.com

exchange

NASDAQ

Description

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

CIK

0001649094

ISIN

US92243G1085

CUSIP

92243G108

Address

825 Industrial Road

Phone

650 837 0111

Country

US

Employee

254

IPO Date

Jun 12, 2020

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep